In immunodeficient mice bearing soft tissue or bone engrafted prostate cancer cells, pancreatic tumors or aggressive B-cell leukemia, a single intravenous infusion of PRDM1/NR4A3 dual KO CAR T-cells resulted in higher antitumor efficacy, T-cell response durability upon rechallenge and overall prolongation of survival compared to conventional CAR T-cell treatment. This evidence concerns the gene PRDM1 and prostate cancer.